Skip to main content
. 2017 Apr 10;8(34):56185–56198. doi: 10.18632/oncotarget.17015

Figure 2. Mucolytic drug NAC enhances 89Zr-Trastuzumab uptake in MUC4 overexpressing JIMT1 tumors.

Figure 2

Standardized maximum uptake of 89Zr-Trastuzumab in JIMT1 (HER2+/MUC4+; dot) and SKBr3 (HER2+/MUC4-; squares) tumors under NAC supplementation (n = 19) and control (n = 20) are shown in the graph with a 89Zr-Trastuzumab PET axial image representative of the tumor (arrow) uptake under NAC exposure (NAC) and control (CTRL). All data points and mean ± SEM are shown, both expressed in SUVmax with ***p < 0.001.